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IMPORTANCE The role of ω-3 polyunsaturated fatty acids for primary prevention of coronary
heart disease (CHD) remains controversial. Most prior longitudinal studies evaluated
self-reported consumption rather than biomarkers.
OBJECTIVE To evaluate biomarkers of seafood-derived eicosapentaenoic acid (EPA; 20:5ω-3),
docosapentaenoic acid (DPA; 22:5ω-3), and docosahexaenoic acid (DHA; 22:6ω-3) and
plant-derived α-linolenic acid (ALA; 18:3ω-3) for incident CHD.
DATA SOURCES A global consortium of 19 studies identified by November 2014.
STUDY SELECTION Available prospective (cohort, nested case-control) or retrospective
studies with circulating or tissue ω-3 biomarkers and ascertained CHD.
DATA EXTRACTION AND SYNTHESIS Each study conducted standardized, individual-level
analysis using harmonizedmodels, exposures, outcomes, and covariates. Findings were
centrally pooled using random-effects meta-analysis. Heterogeneity was examined by age,
sex, race, diabetes, statins, aspirin, ω-6 levels, and FADS desaturase genes.
MAIN OUTCOMES ANDMEASURES Incident total CHD, fatal CHD, and nonfatal myocardial
infarction (MI).
RESULTS The 19 studies comprised 16 countries, 45637 unique individuals, and 7973 total CHD,
2781 fatal CHD, and 7157 nonfatalMI events, withω-3measures in total plasma, phospholipids,
cholesterol esters, and adipose tissue.Median age at baselinewas 59 years (range, 18-97 years),
and 28660 (62.8%)weremale. In continuous (per 1-SD increase)multivariable-adjusted
analyses, theω-3 biomarkers ALA, DPA, andDHAwere associatedwith a lower risk of fatal CHD,
with relative risks (RRs) of 0.91 (95%CI, 0.84-0.98) for ALA, 0.90 (95%CI, 0.85-0.96) for DPA,
and0.90 (95%CI, 0.84-0.96) for DHA. AlthoughDPAwas associatedwith a lower risk of total
CHD (RR, 0.94; 95%CI, 0.90-0.99), ALA (RR, 1.00; 95%CI, 0.95-1.05), EPA (RR, 0.94; 95%CI,
0.87-1.02), andDHA (RR, 0.95; 95%CI, 0.91-1.00)were not. Significant associationswith
nonfatalMIwere not evident. Associations appeared generally stronger in phospholipids and
total plasma. Restricted cubic splines did not identify evidence of nonlinearity in dose responses.
CONCLUSIONS AND RELEVANCE On the basis of available studies of free-living populations
globally, biomarker concentrations of seafood and plant-derived ω-3 fatty acids are
associated with a modestly lower incidence of fatal CHD.
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A review1 of experimental studies and randomized clini-cal trials revealed a protective effect ofω-3 polyunsat-urated fatty acids (PUFAs) on coronary heart disease
(CHD) riskpathwaysandclinical risk factors.However,keycon-
troversies remain. First, randomized clinical trials using fish
oil supplements have foundmixed effects on CHD events.2-8
However,most trials provided supplements for a fewyears or
less and were conducted in patients with preexisting CHD or
at high risk for CHDand takingmultiple cardiovascular drugs.
Furthermore, thebackgrounddietary intake in these trialswas
not usually measured, and many participants may have had
adequate intake from diet alone. Thus, their generalizability
and relevance for long-term effects of dietary ω-3 PUFAs for
primary CHD prevention are uncertain. Second, although a
review9 of several prior observational studies found inverse
associations between seafood-derived ω-3 PUFAs and CHD
death, potential effects onnonfatalmyocardial infarction (MI)
or totalCHDare less clear.This review9additionally found that
most studies also relied on self-reported dietary question-
naires, whichmay produce errors or bias in recall. A previous
review1also found that ahandfulof studieshavemeasuredob-
jective circulating or tissue ω-3 PUFA levels, but such find-
ings could be limitedbypublicationbias. In addition, prior in-
dividual biomarker studies were generally underpowered to
explore potentially relevant differences in effects depending
on underlying participant characteristics, medication use, or
genetic variation. Thus, uncertainties remain about the ef-
fects of ω-3 PUFAs on CHD.
Most studies10,11 have evaluated combined intakes or bio-
marker levels of long-chain ω-3 PUFAs. However, individual
ω-3 PUFAs, including eicosapentaenoic acid (EPA; 20:5ω-3),
docosapentaenoic acid (DPA; 22:5ω-3), and docosahexaenoic
acid (DHA; 22:6ω-3), may have shared and complementary
effects.10 Similarly, most prior research11 has focused on sea-
food-derived long-chain ω-3 PUFAs, and potential CHD ef-
fectsofplant-derivedα-linolenicacid (ALA; 18:3ω-3)are far less
understood.
To address each of these important questions, we devel-
oped a global consortiumof available studieswith circulating
or tissue ω-3 biomarkers and ascertained incident CHD. Our
aimswere to evaluate the associations of individual seafood-
and plant-derived ω-3 PUFAs with incident total CHD, fatal
CHD, andnonfatalMI.Wealsoexploreddose responseandpo-
tentialheterogeneity ineffectsaccordingtokeyunderlyingpar-
ticipant characteristics, including medication use. Our pri-
maryhypothesiswas that biomarkers of long-chainω-3PUFAs
wouldbeassociatedwith a lower riskof incident fatal CHDbut
not nonfatal MI.
Methods
Consortium Formation
TheFattyAcids andOutcomesResearchConsortium (FORCe)
is an extension of the Cohorts for Heart and Aging Research
in Genomic Epidemiology (CHARGE) Fatty Acids Working
Group,12,13 originally developed to investigate effects of ge-
netic variation onbiomarker fatty acid levels. Using direct ex-
pertcontactsandbyreviewingthe literature,we identified large
studies that hadmeasured circulating or tissue biomarkers of
ω-3 PUFAs in general populations and had ascertained inci-
dent CHD. We focused on prospective (cohort, nested case-
control) studies; retrospective studies were included if fatty
acids were measured in adipose tissue at the time of the first
event, given the stability of adipose measures. Studies were
asked to join the consortium and participate in standardized
pooled analyses of biomarker fatty acids and clinical events.
Of 20 identified studies byNovember 2014, only 1 study14 de-
clined to join theconsortium.All cohortparticipantsgavewrit-
ten informed consent according to their local guidelines. All
studies received approval from ethical oversight commit-
tees. Data were deidentified.
Analysis Plan
A standardized analysis protocol was developed and pro-
vided to eachparticipating study, includingharmonizeddefi-
nitions of populations, exposures, outcomes, covariates, ef-
fectmodifiers, andmethods for pooling across studies. These
specific methods are detailed below. An experienced analyst
from each study performed the analysis for that study using
individual-level data and provided all results to the lead in-
vestigator (L.C.D.G.) in standardized electronic forms.
Population
Tounderstand thepotential effectsonprimarypreventionand
minimize reversecausation,participants fromeachstudywere
excluded if they had a prior history ofMI, angina, coronary re-
vascularization,or stroke.All remainingparticipantswithmea-
suredω-3PUFAbiomarker levelswere included in theanalyses.
Fatty Acid Ascertainment
Fatty acid biomarker concentrations were assessed in study-
specific lipidcompartments, includingtotalplasma,erythrocyte
andplasmaphospholipids, cholesterolesters, triglycerides,and
adiposetissue,withallreportedasweightpercentageoftotalfatty
acids.Detailsof fattyacidmeasurementmethodsforeachstudy
are provided in the eMethods in the Supplement.
Assessment of CHD
We evaluated total incident CHD, defined as fatal or nonfatal
MI, CHD death, or sudden cardiac death; nonfatal MI, gener-
ally defined as chest painwith abnormal cardiac enzyme con-
centrationsor serial electrocardiogramchanges; and fatalCHD,
Key Points
Question Are seafood and plant-derived ω-3 fats related to first
coronary heart disease (CHD) events?
Findings In a consortium of 19 studies, biomarkers of seafood and
plant-derived ω-3 fats were associated with a significantly lower
risk of fatal CHD. In contrast, associations with nonfatal myocardial
infarction were generally less robust.
Meaning Blood biomarkers of seafood and plant-derived omega-3
fats are linked to amodestly lower risk of dying from heart attacks.
Consumption of ω-3–rich foods should be encouraged.
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defined as fatal MI, CHD death, or sudden cardiac death. De-
tails of the methods for assessing and defining these out-
comes in each study are provided in eTable 1 in the Supple-
ment. We excluded soft CHD end points (eg, angina,
revascularization) tominimize bias in ascertainment of these
events.
Covariates
Covariateswerestandardizedacross studiesbasedonprespeci-
fied,harmonizeddefinitionsandcategorizations, includingage
(continuous), sex (male, female), race (white, black, and other
study-specific subgroups, if available), clinical center (study-
specific categories, if applicable), bodymass index (BMI [calcu-
lated as the weight in kilograms divided by height in meters
squared], continuous), educational level (less than high school
graduate,highschoolgraduate,somecollegeorvocationalschool,
or college graduate), smoking (current, former, or never or cur-
rentvsnotcurrent, ifformernotassessed),physicalactivity(quar-
tilesofmetabolicequivalentsor, ifmetabolicequivalentsunavail-
able,4categoriesofphysicalor leisureactivityasdefined in the
study), alcohol intake (none, 1-6drinksperweek, 1-2drinksper
day,or>2drinksperday;with14gofalcohol equaling1standard
drink),diabetesmellitus(yesorno,definedastreatmentwithoral
hypoglycemicagents, insulin,orbyusing fastingglucose levels,
orstudy-specificdefinitionsotherwise),treatedhypertension(yes
orno,definedas treatmentwithantihypertensivedrugsorasdi-
agnosedhypertensionotherwise), treatedhypercholesterolemia
(yes or no, defined as treatmentwith lipid-lowering drugs or as
diagnosedhypercholesterolemiaotherwise), regularaspirinuse
(yesorno,categorizedas≥3timesperweek),andbiomarkercon-
centrationsofω-6PUFAlinoleicacid (LA; 18:2ω-6), arachidonic
acid (AA;20:4ω-6),andtotal trans fattyacids (eachcontinuous).
For categorical variables,missing covariate datawere included
as an indicator category.
Statistical Analysis and Pooling
Standardized study-specific analyseswereperformed for each
studyusing individual-level data. Becauseof variability in the
total number of fatty acids assessed across the different as-
says (12-58 fatty acids) and to permit comparison andpooling
of findingsacross thedifferentbiomarker compartments, each
fatty acid was analyzed continuously per 1-SD increase.
For prospective cohorts, Cox proportional hazards regres-
sionmodels estimated the hazard ratio for incident total CHD,
nonfatalMI, and fatalCHD,with follow-up fromthedateofbio-
markermeasurement todate of event, endof follow-up, loss to
follow-up, or death, whichever occurred first. For prospective
andretrospectivematchedcase-control studies, conditional lo-
gisticregressionwasusedtoestimatethehazardratio(ifmatched
on time to event) or odds ratio. All analyses used robust SEs.
For pooled meta-analyses, hazard ratios and odds ratios
were considered to approximate relative risks (RRs). Meta-
analysiswasperformedusing randomeffectsmodelsusing the
methodofDerSimonian andLaird.15 Resultswere first pooled
separately for each biomarker compartment and then pooled
together. If more than 1 biomarker had been measured in a
given study, main results included the biomarker that might
best representdiet: for long-chainω-3 fatty acids, total plasma
orserummeasureswereused,andforALA,adiposetissuemea-
sures were used in the main results.16
To assess potential noncontinuous associations, we also
evaluated study-specific quintiles for each biomarker com-
partment, performingmeta-analysiswithin eachquintile and
comparingeachquintile-specificpooled result to the firstquin-
tile.To statistically testpotentialnonlineardose responses,we
performed multivariate meta-regression, modeling re-
stricted cubic splines.17 These analyses evaluated total plasma
andphospholipids; cholesterol esters andadipose tissue fatty
acidswerenot evaluatedusing splines because of fewernum-
bers of studies in these compartments.
Overallheterogeneitywasassessedusingthe I2statistic,with
heterogeneityconsideredlowif the I2was less than35%.Hetero-
geneitybyprespecifiedsubgroupswasevaluatedbypooling in-
dividualstudyresultsbasedondefinedstrata, includingage(<60
or≥60years), sex (maleor female), race/ethnicity (white,black,
Hispanic,orChinese),LAandAAbiomarkerconcentrations (less
thanorgreater thanorequal to themedianvalue ineachstudy),
type2diabetes (yesorno), statinuse (yesorno), regular aspirin
use(yesorno),yearofbiomarkersampling(before2000or2000
or later), and (for ALA) EPA, DPA, and DHA biomarker concen-
tration (less than or greater than or equal to the median value
ineachstudy).Effectestimates ineachstudy-specificstratawere
pooled, and the statistical significance of differences between
subgroups of potential sources of heterogeneity was assessed
using meta-regression. In a meta-analysis13 of 7 studies with
available genetic data, we also examined potential interaction
byvariants inFADS (OMIM208150)desaturasegenes (rs174546,
rs968567),poolingstudy-specificestimatesusinganadditivege-
neticmodel (eMethods in the Supplement).Within each study,
interactiontermsforeachsingle-nucleotidepolymorphism(SNP)
were constructed as a cross-product term of the ω-3 PUFA bio-
marker (continuous) by the SNP (ordinal: 0, 1, or 2 T alleles), in-
cluding the main effects in the model; these interaction terms
were pooled usingmeta-analysis.
Meta-analyseswereperformedusingSTATAstatistical soft-
ware, version 12 (StataCorp).We considered 2-tailedP< .05 to
be statistically significant.
Sensitivity Analyses
Several sensitivity analyses were performed. We also per-
formedcontinuousmeta-analysisusingabsolute (percentageof
fatty acids), rather than study-specific, units. Tominimize po-
tential reverse causation attributable to preexisting subclinical
disease,weexcludedcases identified inthefirst2yearsafterbio-
marker sampling. To minimize exposure misclassification at-
tributable to within-person changes in biomarker levels over
time, we censored participants after the first 6 years of follow-
up. We performed additional analyses limited to prospective
studies only and thosewithout self-reported CHD events.
Results
Characteristics of Studies and Participants
The 19 studies18-35 included 45637 unique participants from
16countries, including theUnitedStates,Australia,CostaRica,
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Finland, France, Germany, Ireland, Israel, Italy, Norway, Sin-
gapore, theSovietUnion, Spain, Sweden, Switzerland, and the
United Kingdom (Table 1 and eMethods in the Supplement).
Mostwere prospective cohort18,20,25-27,32,34,35 (n = 10 studies)
or prospective nested case-control21,23,24,28-31,33 (n = 7) stud-
ies; 2were retrospectivecase-control studies19,22 thatusedadi-
pose tissue biomarkers. Biomarker types included phospho-
lipids (plasma or erythrocyte) (n = 10), total plasma (n = 6),
adipose tissue (n = 4), and cholesterol esters (n = 1); 2 studies
(Nurses’Health Study [NHS]30 I andHealth Professionals Fol-
low-up Study [HPFS]23) measured total plasma and erythro-
cytephospholipids.Asexpected,ω-3PUFAconcentrationsand
distributions varied across biomarker types and study assays
(eTable 2 and eTable 3 in the Supplement), with coefficients
of variation less than 10% formost fatty acids andbiomarkers
(eMethods in theSupplement). For example,medianALAcon-
centrations were generally higher in adipose (0.72% of total
fatty acids) than in circulatingbiomarkers (0.20%of total fatty
acids),whereas EPA,DPA, andDHAconcentrationswere gen-
erally higher in phospholipids than in other compartments,
consistent with prior reports.16,36
Medianageatbaselinewas59years (range, 18-97years),and
28660participants (62.8%)weremale (eTable 4 in the Supple-
ment). During a median 10 years of follow-up (range, 1.3-42
Table 1. Baseline Characteristics of 19 Studies and 45637 ParticipantsWith BiomarkerMeasures of ω-3 Fatty Acidsa
Study Country
Study
Design
Age, Mean,
y
Sex, %
Male
Biomarker
Compartment
Year of Blood
Sampling
Fatty Acids
Assessed
Coronary Heart
Disease Outcomes
ARIC18 United States PC 54 48 Plasma phospholipid 1987-1989 ALA, DPA,
EPA, DHA
Total CHD
Costa Rican adults
study19
Costa Rica RCC 59 72 Adipose tissue 1995-2004 ALA, DPA,
EPA, DHA
Nonfatal MI
CHS20 United States PC 74 40 Plasma phospholipid 1992-1993 ALA, DPA,
EPA, DHA
Total CHD, nonfatal
MI, fatal CHD
EPIC-Norfolk21 United Kingdom PCC 63 49 Plasma phospholipid 2001-2004 ALA, DPA,
EPA, DHA
Total CHD, nonfatal
MI, fatal CHD
EURAMIC22 Finland, Norway,
Scotland, Ireland,
Germany,
Switzerland,
Spain, Israel, and
Russia
RCC 54 100 Adipose tissue 1991-1992 ALA, DPA,
DHA
Nonfatal MI
HPFS23 United States PCC 64 100 Total plasma,
erythrocyte
phospholipid
1994
1994
ALA, DPA,
EPA, DHA
Total CHD, nonfatal
MI, fatal CHD
InCHIANTI24 Italy PCC 65 45 Total plasma 1998-2000 ALA, EPA,
DHA
Total CHD
KIHD25 Finland PC 52 100 Total plasma 1991-1992 ALA, DPA,
EPA, DHA
Total CHD, nonfatal
MI, fatal CHD
MCCS26 Australia PC 56 49 Plasma phospholipid 1990-1994 ALA, DPA,
EPA, DHA
Fatal CHD
MESA27 United States PC 62 47 Plasma phospholipid 2000-2002 ALA, DPA,
EPA, DHA
Total CHD, nonfatal
MI, fatal CHD
NSHDS I28 Sweden PCC 55 79 Plasma phospholipid 1995 ALA, DPA,
EPA, DHA
Total CHD
NSHDS II29 Sweden PCC 55 62 Plasma phospholipid 2007 ALA, DPA,
EPA, DHA
Total CHD, nonfatal
MI, fatal CHD
NHS I30 United States PCC 60 0 Total plasma,
erythrocyte
phospholipid
1989-1990
1989-1990
ALA, DPA,
EPA, DHA
Total CHD, nonfatal
MI, fatal CHD
PHS31 United States PCC 69 100 Erythrocyte
phospholipid
1995-2000 ALA, DPA,
EPA, DHA
Total CHD, nonfatal
MI, fatal CHD
SHHEC32 Scotland PC 49 52 Adipose tissue 1984-1986 DPA, DHA Total CHD, nonfatal
MI, fatal CHD
SCHS33 Singapore PCC 66 65 Total plasma 1994-2005 ALA, EPA,
DHA
Total CHD, nonfatal
MI, fatal CHD
3C Study34 France PC 75 39 Total plasma 1999-2000 ALA, DPA,
EPA, DHA
Total CHD
ULSAM 5035 Sweden PC 50 100 Cholesterol esters 1970 ALA, EPA,
DHA
Total CHD, nonfatal
MI, fatal CHD
ULSAM 7035 Sweden PC 71 100 Adipose tissue 1990 ALA, DPA,
EPA, DHA
Total CHD, nonfatal
MI, fatal CHD
Abbreviations: ALA, α-linolenic acid; ARIC, Atherosclerosis Risk in Communities;
CHD, coronary heart disease; CHS, Cardiovascular Health Study; DHA,
docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic
acid; EPIC-Norfolk, European Prospective Investigation of Cancer (Norfolk);
EURAMIC, European Study on Antioxidants, Myocardial Infarction and Cancer;
HPFS, Health Professionals Follow-up Study; InCHIANTI, Invecchiare in Chianti;
KIHD, Kuopio Ischaemic Heart Disease Risk Factor Study; MCCS, Melbourne
Collaborative Cohort Study; MESA, Multi-Ethnic Study of Atherosclerosis; MI,
myocardial infarction; NSHDS, Northern Sweden Health and Disease Study;
NHS, Nurses’ Health Study; PC, prospective cohort; PCC, prospective nested
case-control; PHS, Physicians’ Health Study; RCC, retrospective case-control;
SHHEC, Scottish Heart Health Extended Cohort; SCHS, Singapore Chinese
Health Study; ULSAM, Uppsala Longitudinal Study of Adult Men; 3C Study,
Three-City study.
a Characteristics described at time of fatty acid biomarker measurement.
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years), 7973 incident CHD events, 7157 nonfatal MIs, and 2781
fatal CHD events occurred. Because not all studies ascertained
everyexposureandoutcome (Table 1), casesofnonfatalMIand
fatal CHD do not sum to the number of total CHD cases. Medi-
cationusevariedacrossstudies;bydesign,allparticipants inthe
analysis were free of prevalent CHD or stroke (eTable 5 in the
Supplement).Mostparticipantswerewhite, but theCardiovas-
cular Health Study (CHS)20 and Multi-Ethnic Study of Athero-
sclerosis (MESA)27 includedrelativelyhigherproportionsofAfri-
canAmericanindividuals (12.3%and24.7%,respectively);MESA
and the Costa-Rican Case-Control Study of Myocardial Infarc-
tion (CostaRican adults study)19 includedHispanic individuals
(24.9% and 100%, respectively), and MESA27 and the Singa-
pore Chinese Health Study (SCHS)33 included Chinese partici-
pants (25.0%and100%,respectively).Acrossall studies, theme-
dian BMIwas 26, and generally up to 30%of participants were
current smokers, except for higher rates in the Scottish Heart
Health Extended Cohort32 (44.6%) and Uppsala Longitudinal
Study of Adult Men35 50 (51.0%). Alcohol intake was modest,
withmostparticipants consumingup to 1drinkperday.Fishoil
supplementationwas infrequentlyassessedacross studies;use
was low(0%-4%ofparticipants) in5of6studieswith thesedata
(eTable6 intheSupplement);only theEuropeanProspective In-
vestigation of Cancer (Norfolk) (EPIC-Norfolk)21 had a higher
prevalence (33%).
EPA, DPA, and DHA for Incident CHD
Incontinuous (per 1-SD increase)multivariable-adjustedanaly-
ses, eachω-3 PUFAwas associatedwith an approximately 9%
lower risk of fatal CHD, with RRs of 0.91 (95% CI, 0.82-1.00)
for EPA, 0.90 (95% CI, 0.85-0.96) for DPA, and 0.90 (95% CI,
0.84-0.96) for DHA (Figure 1 and Figure 2). There was mod-
erate heterogeneity in this association for EPA and DHA
(I2 = 37% for both) and low heterogeneity for DPA and DHA
(I2 = 0%and31%, respectively) (Figure 1andFigure2).Thesum
of EPA, DPA, and DHA was associated with an 11% lower risk
of fatal CHD (eFigure 1 in the Supplement). By contrast, none
of the long-chainω-3PUFAswere significantly associatedwith
nonfatalMI (Table 2).We found thatDPA, butnotEPAorDHA,
wasassociatedwithasignificantly lower riskof totalCHD,with
RRsof0.94 (95%CI, 0.90-0.99), 0.94 (95%CI, 0.87-1.02), and
0.95 (95% CI, 0.91-1.00), respectively (Table 2).
SomedifferenceswereobservedwhenEPA,DPA, andDHA
wereevaluatedacrossquintiles(eTable7intheSupplement).Up-
per quintiles of EPA andDHAwere associatedwith a lower risk
ofnonfatalMI (quintile5vsquintile 1comparison:RR,0.71 [95%
CI,0.56-0.90]vs0.87 [95%CI,0.78-0.97]).TopquintilesofDPA
and DHAwere associated with a lower risk of fatal CHD (quin-
tile 5 vs quintile 1 comparison: RR, 0.76 [95%CI, 0.65-0.90] vs
0.77 [95%CI, 0.64-0.89]) (eTable 7 in the Supplement). Across
biomarker types, inverse associations were generally stronger
in the phospholipid and total plasma compartments (Table 2);
heterogeneitydecreasedwhenadiposetissueandcholesteroles-
ter estimates were excluded frommeta-analyses.
ALA and Incident CHD
In continuous analysis, ALA was associated with a 9% lower
risk of fatal CHD (RR, 0.91 [95% CI, 0.84-0.98]) (Figure 1) but
not total CHD or nonfatal MI. For ALA, no single biomarker
compartmentconsistentlyhadstrongerassociationsacrossout-
comes.
Restricted Cubic Spline Analysis
Restricted cubic splines did not identify evidence of nonlin-
ear associations of any of the ω-3 PUFA biomarkers and out-
comes in total plasma or phospholipids (P for nonlinearity >
.05 for each) (eFigure 2 in the Supplement).
EffectModification
Nosignificantdifferences in associationsofω-3PUFAbiomark-
ers with incident CHD events were observed by age, sex, ω-6
PUFA (LA or AA) concentrations, type 2 diabetes status, statin
use, regularaspirinuse,yearofbiomarkersampling,or (forALA)
EPA,DPA,andDHAconcentrations (P forheterogeneity> .05for
each) (eTable 8 in the Supplement). In a post hoc meta-
regression, we observed no significant differences in associa-
tions by median length of follow-up (<10 or ≥10 years) (P for
heterogeneity > .05 for each). Effect modification was sug-
gestedbyethnicity.Comparedwithwhite individuals,ALAwas
associatedwith a significantly lower risk of nonfatalMI among
African American individuals (P for heterogeneity = .001). For
EPA, ALAwas associatedwith a significantly lower risk of total
CHDandnonfatalMIamongChineseparticipants (P forhetero-
geneity = .02and .01, respectively).Among7studies10,17,19,33-35
with SNP data (eTable 9 in the Supplement), no significant in-
teractionwasidentifiedbyFADSdesaturasegenevariants(eTable
10 in the Supplement).
Sensitivity Analyses
Compared with the main findings, no appreciable differ-
enceswereobservedafterexcludingcases identified in the first
2years after biomarker sampling, censoringparticipants at the
first 6 years of follow-up, excluding retrospective studies, or
excluding studies with self-reported events (eTable 11 in the
Supplement). For 2 studies23,30 that analyzed phospholipids
inaddition to total plasma (NHS IandHPFS), resultswere simi-
lar when phospholipid results from these studies were used
in place of total plasma in the meta-analysis.
Discussion
In this consortium which pooled individual-level harmonized
analyses from 19 studies, including 45637 unique participants
and nearly 8000 first CHD events in 16 countries, the ω-3 bio-
markers ALA, DPA, and DHAwere associated with a modestly
lower risk of fatal CHD. Themagnitude of observed effect sizes
for fatal CHD (approximately 9% per 1-SD increase) are consis-
tent with findings for cardiac death from a meta-analysis8 of
trials. In contrast, associationswithnonfatalMIwere generally
less robust. Across these diverse studies, findingswere consis-
tent by age, sex, ω-6 PUFALA andAA levels, year of biomarker
sampling, presenceor absenceofdiabetes, statinuse, andaspi-
rin use. By contrast, effect modification by ethnicity was ob-
served for select exposure-outcome pairings. Separate analy-
ses by biomarker compartment provided further insights,with
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generallystrongerinverseassociationsinphospholipidsandtotal
plasma forEPA,DPA, andDHA.This investigationprovides the
most comprehensive estimates to date of the associations be-
tween seafood and plant-basedω-3 PUFAs, assessed using bio-
markers,andprimaryincidenceofCHDingenerallyhealthy,free-
living populations around theworld.
In randomized clinical trials, long-chain ω-3 PUFAs ben-
efit multiple major cardiovascular risk factors, including tri-
glyceride levels, bloodpressure, heart rate, heart rate variabil-
ity, endothelial function, andmyocardial oxygen demand.1,10
Compared with many other single nutrients, these demon-
stratedphysiologic benefits provide strong biologic plausibil-
Figure 1. Relative Risk (RR) of Fatal Coronary Heart Disease (CHD) per 1-SD Increase in the Biomarkers
α-Linolenic Acid (ALA; 18:3ω-3) and Eicosapentaenoic Acid (EPA; 20:5ω-3)
Weight,
%
No.
of CasesStudy
Total plasma
RR
(95% CI)
0.34123HPFS 1.42 (0.37-5.46)
9.83168KIHD 0.75 (0.62-0.91)
1.1557NHS I 0.75 (0.37-1.55)
0.63292SCHS 0.70 (0.26-1.86)
Phospholipid
18.02516CHS 0.84 (0.76-0.93)
2.5580NSHDS II 1.39 (0.87-2.22)
4.58167PHS 1.21 (0.87-1.69)
17.42507EPIC-Norfolk 0.92 (0.83-1.02)
14.22MESA 0.85 (0.74-0.98)47
11.46202MCCS 0.86 (0.72-1.02)
11.95Subtotal I2 = 0.0%, P = .83 0.76 (0.63-0.91)
68.25Subtotal I2 = 43.4%, P = .12 0.90 (0.82-0.98)
Adipose tissue
1.7983ULSAM 70 1.03 (0.58-1.82)
1.79Subtotal 1.03 (0.58-1.82)
Cholesterol esters
18.02398ULSAM 50 1.02 (0.92-1.13)
18.02Subtotal 1.02 (0.92-1.13)
100.000.91 (0.84-0.98)Overall I2 = 44.5%, P = .02
Total cases 2640
Weight,
%
1.41.20.80.60.40.2 1.0
EPA RR (95% CI)
1.61.41.21.00.6 0.8
ALA RR (95% CI)
No.
of CasesStudy
Total plasma
RR
(95% CI)
1.48123HPFS 0.95 (0.43-2.10)
16.84168KIHD 1.00 (0.86-1.17)
0.9744NHS I 0.80 (0.30-2.15)
1.16292SCHS 0.33 (0.14-0.82)
Phospholipid
4.46516CHS 0.72 (0.47-1.11)
1.9080NSHDS II 0.39 (0.19-0.77)
6.20167PHS 0.92 (0.65-1.31)
20.65507EPIC-Norfolk 0.89 (0.79-1.00)
1.50MESA 0.59 (0.27-1.29)47
16.99202MCCS 0.91 (0.78-1.06)
20.45Subtotal I2 = 47.4%, P = .13 0.80 (0.51-1.25)
51.70Subtotal I2 = 33.5%, P = .18 0.85 (0.74-0.97)
Adipose tissue
11.0274ULSAM 70 1.08 (0.86-1.37)
11.02Subtotal 1.08 (0.86-1.37)
Cholesterol esters
16.84398ULSAM 50 0.97 (0.83-1.14)
16.84Subtotal 0.97 (0.83-1.14)
100.000.91 (0.82-1.00)Overall I2 = 36.5%, P = .05
Total cases 2613
Favors
higher risk
Favors
lower risk
Favors
higher
risk
Favors
lower
risk
Estimates were pooled using random
effects meta-analysis. CHS indicates
Cardiovascular Health Study20;
EPIC-Norfolk, European Prospective
Investigation of Cancer (Norfolk)21;
HPFS, Health Professionals Follow-up
Study23; KIHD, Kuopio Ischaemic
Heart Disease Risk Factor Study25;
MCCS, Melbourne Collaborative
Cohort Study26; MESA, Multi-Ethnic
Study of Atherosclerosis27; NHS,
Nurses’ Health Study30; NSHDS,
Northern Sweden Health and Disease
Study28,29; PHS, Physician’s Health
Study31; SCHS, Singapore Chinese
Health Study33; and ULSAM, Uppsala
Longitudinal Study of Adult Men.35
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ity to support an effect on clinical events. Both EPA and DHA
arealsoprecursors tobioactive lipidmetabolites, includingspe-
cialized proresolving mediators36 and cytochrome P450–
generatedmonoepoxides,37 thatcouldcontribute to lowerCHD
risk. Our findings are consistent with prior experimental evi-
dence that long-chain ω-3 PUFAs may have membrane stabi-
lizing actions in the setting of ischemia-induced ventricular
fibrillation1,38 andobservational evidence indicating that ben-
efits of fish consumption are most related to arrhythmic
events39 and fatal CHD.40
Use of biomarkers allowed separate investigation of each
ω-3 PUFA. Of interest, EPA, DPA, and DHA were similarly as-
sociatedwith lower riskof fatalCHD.Biomarker levels of these
fatty acids are onlymoderately interrelated (eg, r = 0.43, 0.51,
Figure 2. Relative Risk (RR) of Fatal Coronary Heart Disease (CHD) per 1-SD Increase in the Biomarkers
Docosapentaenoic Acid (DPA; 22:5ω-3) and Docosahexaenoic Acid (DHA; 22:6ω-3)
Weight,
%
1.0 5.00.2
DPA RR (95% CI)
No.
of CasesStudy
Total plasma
RR
(95% CI)
0.05123HPFS 4.16 (0.23-74.73)
13.25168KIHD 0.84 (0.70-1.00)
0.0857NHS I 1.56 (0.17-14.40)
Phospholipid
2.22516CHS 0.72 (0.47-1.11)
1.6980NSHDS II 0.86 (0.52-1.41)
2.68167PHS 1.11 (0.75-1.64)
42.94507EPIC-Norfolk 0.87 (0.79-0.96)
0.23MESA 0.29 (0.08-1.12)70
18.70202MCCS 0.99 (0.85-1.15)
13.38Subtotal I2 = 0.0%, P = .48 0.84 (0.71-1.01)
68.46Subtotal I2 = 27.6%, P = .23 0.91 (0.80-1.02)
Adipose tissue
4.7779ULSAM 70 0.97 (0.72-1.30)
13.37SHHEC 143 0.96 (0.81-1.15)
18.14Subtotal I2 = 0.0%, P = .96 0.96 (0.83-1.12)
100.000.90 (0.85-0.96)Overall I2 = 0.0%, P = .002
Total cases 2112
Weight,
%
1.00.8 1.20.60.4
DHA RR (95% CI)
No.
of CasesStudy
Total plasma
RR
(95% CI)
1.38123HPFS 0.74 (0.43-1.26)
9.06168KIHD 0.84 (0.71-1.01)
0.3057NHS I 0.48 (0.15-1.55)
5.91292SCHS 0.71 (0.56-0.90)
Phospholipid
17.20516CHS 0.84 (0.76-0.93)
1.4480NSHDS II 0.67 (0.40-1.13)
3.28167PHS 1.01 (0.72-1.40)
16.65507EPIC-Norfolk 0.86 (0.78-0.96)
4.38MESA 0.86 (0.65-1.14)47
11.73202MCCS 0.98 (0.85-1.13)
16.65Subtotal I2 = 0.0%, P = .57 0.78 (0.69-0.90)
54.68Subtotal I2 = 0.0%, P = .46 0.88 (0.83-0.93)
Adipose tissue
4.5981ULSAM 70 0.98 (0.74-1.29)
9.45143SHHEC 1.00 (0.84-1.18)
14.04Subtotal I2 = 0.0%, P = .91 0.99 (0.86-1.15)
Cholesterol esters
14.62398ULSAM 50 1.02 (0.91-1.15)
14.62Subtotal 1.02 (0.91-1.15)
100.000.90 (0.84-0.96)Overall I2 = 31.2%, P = .002
Total cases 2781
Favors
higher
risk
Favors
lower
risk
Favors
higher risk
Favors
lower risk
Estimates were pooled using random
effects meta-analysis. CHS indicates
Cardiovascular Health Study20;
EPIC-Norfolk, European Prospective
Investigation of Cancer (Norfolk)21;
HPFS, Health Professionals Follow-up
Study23; KIHD, Kuopio Ischaemic
Heart Disease Risk Factor Study25;
MCCS, Melbourne Collaborative
Cohort Study26; MESA, Multi-Ethnic
Study of Atherosclerosis27; NHS,
Nurses’ Health Study30; NSHDS,
Northern Sweden Health and Disease
Study28,29; PHS, Physician’s Health
Study31; SCHS, Singapore Chinese
Health Study33; SHHEC, Scottish
Heart Health Extended Chart32; and
ULSAM, Uppsala Longitudinal Study
of Adult Men.35
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and 0.13 for EPA and DHA, EPA and DPA, and DPA and DHA,
respectively).41 Thus, observed associations for any 1 of these
fattyacidsareunlikely tobe fullyexplainedbytheothers.Com-
pared with EPA and DHA, comparatively less is known about
the molecular and physiologic effects of DPA; a previous
study10 suggests that DPA may inhibit ex vivo collagen-
stimulatedplatelet aggregation, thromboxaneproduction, and
cyclooxygenase 1 activity. In addition,whereas circulatingand
tissue levels of EPA and DHA are strongly influenced by di-
etary seafood consumption, DPA concentrations appear to be
mainlyderived fromendogenouselongationofEPA; intercon-
version between DPA and DHA is very limited.10
Givendiverse global dietary sources, the effects ofALAon
CHD are of particular interest. However, a meta-analysis11 of
prior reports of dietary and biomarker ALA and CHD risk re-
vealed inconsistency,perhapsowing tomethodologicandana-
lytic differences in these investigations. A key strength of our
analysiswas theprespecified, harmonizedanalytic planusing
individual-level data within each study, which allowed con-
sistent assessmentof howALA relates toCHD. In addition, the
inclusionof 19studiesminimized theeffectofpublicationbias,
wherein studies with positive findings are more likely re-
ported. Comparedwith prior work,42 we also took advantage
ofa far largernumberofevents (eg,>4-fold larger for fatalCHD)
Table 2. Pooled RRs of Total CHD, Nonfatal MI, and Fatal CHD per 1-SD Increase in ALA, EPA, DHA, and DPAa
Exposure and Biomarker
Total CHD Nonfatal MI Fatal CHD
No. of
Casesb
No. of
Studies RR (95% CI)
No. of
Cases
No. of
Studies RR (95% CI)
No. of
Cases
No. of
Studies RR (95% CI)
ALA
Total plasma 2286 6 1.05
(0.91-1.20)
1578 4 1.07
(0.87-1.31)
640 4 0.76
(0.63-0.91)
Phospholipids 3719 7 0.98
(0.92-1.06)
1790 5 0.95
(0.87-1.03)
1519 6 0.90
(0.82-0.98)
Adipose tissue 206 1 1.09
(0.74-1.62)
2385 3 0.71
(0.26-1.95)
83 1 1.03
(0.58-1.82)
Cholesterol esters 749 1 1.00
(0.92-1.08)
364 1 0.90
(0.80-1.01)
398 1 1.02
(0.92-1.13)
Overall 6960 15 1.00
(0.95-1.05)
6117 13 0.95
(0.87-1.05)
2640 12 0.91
(0.84-0.98)
EPA
Total plasma 2194 6 0.93
(0.97-1.11)
1499 4 0.89
(0.69-1.14)
627 4 0.80
(0.51-1.25)
Phospholipids 3703 7 0.89
(0.81-0.99)
1790 5 0.91
(0.79-1.04)
1519 6 0.85
(0.74-0.97)
Adipose tissue 181 1 1.19
(1.05-1.33)
1734 2 0.85
(0.67-1.09)
74 1 1.08
(0.86-1.37)
Cholesterol esters 749 1 0.97
(0.88-1.07)
364 1 0.95
(0.83-1.09)
398 1 0.97
(0.83-1.14)
Overall 6827 15 0.94
(0.87-1.02)
5387 12 0.92
(0.83-1.01)
2613 12 0.91
(0.82-1.00)
DPA
Total plasma 1412 4 0.93
(0.84-1.02)
1111 3 0.94
(0.81-1.08)
348 3 0.84
(0.71-1.01)
Phospholipids 3703 7 0.92
(0.86-0.97)
1767 5 0.95
(0.86-1.06)
1542 6 0.91
(0.80-1.02)
Adipose tissue 1092 2 1.01
(0.94-1.08)
3137 4 0.98
(0.88-1.11)
222 2 0.96
(0.83-1.12)
Cholesterol esters NA NA NA NA NA NA NA NA NA
Overall 6207 13 0.94
(0.90-0.99)
6015 12 0.97
(0.93-1.02)
2112 11 0.90
(0.85-0.96)
DHA
Total plasma 2425 6 0.91
(0.82-1.02)
1866 4 0.91
(0.84-0.98)
640 4 0.78
(0.69-0.90)
Phospholipids 3703 7 0.93
(0.89-0.97)
1790 5 0.97
(0.91-1.03)
1519 6 0.88
(0.83-0.93)
Adipose tissue 1096 2 1.05
(0.95-1.16)
3137 4 0.89
(0.68-1.18)
224 2 0.99
(0.86-1.15)
Cholesterol esters 749 1 1.01
(0.93-1.09)
364 1 1.03
(0.81-1.15)
398 1 1.02
(0.91-1.15)
Overall 7973 16 0.95
(0.91-1.00)
7157 14 0.96
(0.92-1.01)
2781 13 0.90
(0.84-0.96)
Abbreviations: ALA, α-linolenic acid; CHD, coronary heart disease; DHA,
docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic
acid; MI, myocardial infarction; NA, not applicable; RR, relative risk.
a Continuous estimates were pooled using random effects meta-analysis.
b Because not all studies ascertained every exposure and outcome (Table 1),
cases of nonfatal MI and fatal CHD do not sum to the number of total CHD
cases.
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and observed a similarly lower risk of fatal CHD for ALA as for
long-chainω-3PUFAs.Mechanistically, these findings are sup-
ported by effects of ALA on thrombosis, inflammation, ar-
rhythmia, and endothelial function.43-47 Our findings, com-
bined with relative affordability, global accessibility, and
sustainability of ALA,48 support the potential importance of
ALA for improving global cardiovascular health.
The largenumber of cases in our analysis and inclusionof
multiple ethnic subgroups allowed us to explore potential ef-
fect modification in ω-3 PUFAs and CHD outcome associa-
tions by race/ethnicity. The stronger effects among African
AmericanandChinese individuals for selectω-3–outcomepair-
ings could be attributable to differences in consumption pat-
terns, truebiologic diversity inpathophysiologic pathways, or
chance. For instance, preparation methods among Chinese
populations could differ from that amongwhite populations,
with raworsteamedfish in the formerpopulationvsmoredeep
fried fish in the latter. Differential pathophysiologic path-
ways for cardiometabolic risk have also been documented
among Asian vs white populations; for example, Asian indi-
vidualsdeveloptype2diabetesatamuch lowerBMI thanwhite
individuals,49,50 and at least 3 meta-analyses51-53 have re-
ported a protective effect of seafood-derived ω-3 fatty acids
on incident diabetes among Asian individuals, but not white
individuals. Finally, our findingsof effectmodificationby race
couldbeattributable tochance; fewstudieswereavailablewith
AfricanAmerican (n = 2 studies: CHS andMESA) andChinese
subgroups (n = 2 studies: SCHS and MESA).27,33 Our results
highlight the need for further work to better understand dif-
ferences in associations by race for ω-3 fatty acids and inci-
dent CHD phenotypes.
Randomizedclinicaltrialsoffishoilsupplementshavefound
mixed effects, although overall pooled findings indicate a ben-
efit in lowering risk of cardiac death,8 consistentwith our find-
ings.Our investigationtestsuniqueandseparatequestionsfrom
these trials attributable to differences in the ω-3 PUFA source
(dietary in our study vs supplements in trials), population (pri-
marypreventionvs secondarypreventionorhigh risk), anddu-
ration(habitual intakevsshort-termsupplementation).Incohort-
harmonized,stratifiedanalyses,wefoundlittleevidenceofeffect
modification by statin or aspirin use,which have beenhypoth-
esizedtoreducebenefitsofω-3 fattyacids.54Wealso foundlittle
evidenceofeffectmodificationbycirculatingω-6PUFAs (LAor
AA), which have been hypothesized but never found in hu-
mans to reduce cardiovascular benefits of ω-3 PUFAs.55 Alto-
gether, our findings suggest that seafoodandplant-derivedω-3
PUFAs are beneficial for fatal CHD prevention across diverse
population subgroups.
Our stratification by biomarker type provides new in-
sights onwhich lipid compartmentsmaymost influenceCHD.
Adipose tissue has been suggested for measurement of fatty
acids because it reflects long-term dietary intake (approxi-
mately 1 year).56However, EPAandDHAaremorehighly con-
centrated in phospholipids than other compartments, and
phospholipids also respond rapidly todietary changes57,58 and
maybest reflecteffectsonmembranereceptors.1Thebest com-
partment for assessing ALA has also been unclear, with pos-
sible advantages to adipose tissue16 but relatively little prior
evaluation of other compartments. Our findings suggest gen-
erally stronger inverseassociationswithCHDforEPA,DPA,and
DHA in phospholipids and total plasma, although fewer esti-
mates and caseswere available for adipose andcholesterol es-
ters compartments, decreasing precision. Our results sup-
port use of phospholipids or total plasma for long-chain ω-3
PUFA exposure and a need for further investigation of opti-
mal biomarkers for assessing ALA.
Our analysis has several important strengths. Use of bio-
markers providedmeasures of exposure free of recall error and
allowed separate evaluation of different ω-3 PUFAs and differ-
ent circulating and tissue lipid compartments. We used stan-
dardized definitions and modeling for the populations, expo-
sures, outcomes, covariates, effect modifiers, and analysis,
reducing heterogeneity and potential investigator bias. Most
studies18-25,27-35usedcentralizedadjudicationprocessesor reg-
istry linkagerather thanself-reportalone inascertainingevents,
reducing informationbias.Findingsweresimilar inseveral sen-
sitivity analyses, suggesting the robustness of results to vary-
ing assumptions.Our inclusionof all available studies substan-
tially reduces the potential for publication bias. The studies
included both sexes, multiple races, and a range of socioeco-
nomic statuses across 16 countries, increasing generalizability.
Potential limitations should be considered. Relatively few
studies19,22,32,35wereavailable forsomelipidcompartments (eg,
adipose, cholesterol esters), limiting inference for these spe-
cificcompartments.Allcohortsassessedω-3PUFAexposureonce
atbaseline, andchangesover timewouldattenuate findings to-
ward the null, causing underestimation of associations. Re-
duced statistical power inquintile analyses andspline analyses
made it difficult to ascertain the specific shape of dose re-
sponses. Becauseweanalyzedobservational studies, biomark-
ers and risk factors were not evenly distributed by randomiza-
tion of study participants; hence, unmeasured or residual
confounding cannotbeexcluded, andω-3biomarkermeasures
may in part be markers of a long-term healthy lifestyle. How-
ever, our findingswere independent of a rangeofmajor cardio-
vascularriskfactors,andtherelativespecificityfor fatalCHDand
knownbiologic effects ofω-3PUFAs also argue against residual
confounding as the sole explanation for our findings. Because
our findings reflecthabitualω-3exposure forprimaryCHDpre-
vention, our results do not imply that fish oil supplementation
will necessarily reduce CHD events, particularly in the context
ofshort-termtreatmentor inthosewithpreexistingCHD.Aware-
nessofω-3PUFAs, laboratoryascertainmentmethods,andmedi-
cal treatment of hypertension, hypercholesterolemia, diabe-
tes,angina,andMIhavechangedovertimeandcouldcontribute
to heterogeneity of results; however, we observed no signifi-
cantdifferences in the results for studiesassayingω-3PUFAlev-
els before vs after the year 2000.
Conclusions
Our pooled collaboration of global studies using biomarkers
ofω-3PUFAs inparticipantswithoutprevalentCHDreveals that
habitual consumption of seafood and plant-based ω-3 PUFAs
is associated with a modestly lower risk of fatal CHD.
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